Ernexa Therapeutics (NASDAQ:ERNA) Issues Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) announced its earnings results on Monday. The company reported ($6.95) EPS for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00), FiscalAI reports.

Ernexa Therapeutics Stock Down 4.2%

Shares of ERNA traded down $0.32 during mid-day trading on Monday, hitting $7.21. 483,898 shares of the company traded hands, compared to its average volume of 912,916. Ernexa Therapeutics has a 1-year low of $3.18 and a 1-year high of $100.46. The company has a market capitalization of $8.44 million, a PE ratio of -0.10 and a beta of 1.88. The business has a 50 day moving average of $5.89 and a 200 day moving average of $21.13.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of Ernexa Therapeutics to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. Finally, Brookline Capital Markets assumed coverage on shares of Ernexa Therapeutics in a report on Thursday. They issued a “buy” rating and a $30.00 target price for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $30.00.

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.